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toABSTRACT
Purpose: To prospectively assess the Sentry bioconvertible inferior vena cava (IVC) filter in patients requiring temporary protection
against pulmonary embolism (PE).
Materials and Methods: At 23 sites, 129 patients with documented deep vein thrombosis (DVT) or PE, or at temporary risk of
developing DVTor PE, unable to use anticoagulation were enrolled. The primary end point was clinical success, including successful filter
deployment, freedom from new symptomatic PE through 60 days before filter bioconversion, and 6-month freedom from filter-related
complications. Patients were monitored by means of radiography, computerized tomography (CT), and CT venography to assess
filtering configuration through 60 days, filter bioconversion, and incidence of PE and filter-related complications through 12 months.
Results: Clinical success was achieved in 111 of 114 evaluable patients (97.4%, 95% confidence interval [CI] 92.5%–99.1%). The rate
of freedom from new symptomatic PE through 60 days was 100% (n ¼ 129, 95% CI 97.1%–100.0%), and there were no cases of PE
through 12 months for either therapeutic or prophylactic indications. Two patients (1.6%) developed symptomatic caval thrombosis
during the first month; neither experienced recurrence after successful interventions. There was no filter tilting, migration, embolization,
fracture, or caval perforation by the filter, and no filter-related death through 12 months. Filter bioconversion was successful for 95.7%
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Volume 29 ▪ Number 10 ▪ October ▪ 2018 1351Conclusions: The Sentry IVC filter provided safe and effective protection against PE, with a high rate of intended bioconversion and a
low rate of device-related complications, through 12 months of imaging-intense follow-up.ABBREVIATIONS
CEC ¼ clinical events committee, CI ¼ confidence interval, DVT ¼ deep vein thrombosis, FDA ¼ US Food and Drug Administration,
IDE ¼ investigational device exemption, IVC ¼ inferior vena cava, PE ¼ pulmonary embolism, SAE ¼ serious adverse event, VTE ¼
venous thromboembolismPulmonary embolism (PE) leads to the hospitalization or
death of approximately 225,000 Americans, 30,000 Cana-
dians, and 300,000 Europeans per year, the incidence having
increased during the past decade (1,2). In the United States,
estimates of the nonfatal occurrence of PE range from
400,000 to 630,000 cases per year (3), and PE is the leading
cause of preventable in-hospital mortality (4), with estimated
annual cumulative costs ranging from $8.5 billion to $19.8
billion (5). Risk factors for PE include a history of deep vein
thrombosis (DVT), recent surgical procedures, hospitalization
for cancer and chronic conditions, prolonged inactivity or
immobility, traumatic injury, obesity, and advanced age (6).
The vast majority of PEs occur within 30 days of the index
event (hospitalization, trauma, surgery) (7–9).
Whereas pharmacologic management with the use of anti-
coagulant agents is the establishedprimary treatment for venous
thromboembolic (VTE) disease, for many patients anti-
coagulation is ineffective, is contraindicated, or has to be dis-
continued during periods of high PE risk. Inferior vena cava
(IVC) filters are recommended for these situations in accor-
dance with careful selection criteria (3,10–12). In response to
complications, such as IVC thrombosis, that have been asso-
ciatedwith permanent IVCfilters, retrievable devices have been
available since 2003 for protection from PE during recognized
periods of transient risk (13). However, even with the increased
education and patient-tracking initiatives following the April
2010 US Food and Drug Administration (FDA) safety
communication (updated in May 2014) advising prompt filter
retrieval “as soon as protection from pulmonary embolism is
no longer needed” (11,14,15), as many as 65%–80% of filters
remain unretrieved, with an associated time-dependent increase
in retrievable-filter–specific complications, including device
tilting, fracture, migration, embolization, thrombosis, IVC
perforation, surgery, and death (4,16–21). Prolonged in-
dwelling time also increases the risk of failure and complica-
tions if filter retrieval is attempted (4,22).
The Sentry bioconvertible IVC filter (Novate Medical,
Galway, Ireland) is designed to provide temporary protec-
tion against PE during transient high-risk periods and then
to bioconvert, avoiding the need for a second (retrieval)
intervention and leaving a patent IVC lumen. Bioconversion
is defined as the release of filter arms from the filtering cone
in the central portion of the IVC lumen after hydrolytic
degradation of the bioabsorbable filament. Through 180
days in a preclinical study on the Sentry filter in an ovine
model, there were no filter-related complications, and thedevices were all bioconverted and stably incorporated,
leaving all IVCs patent (23). Interim results are reported
here from a prospective trial undertaken to evaluate the
safety and efficacy of the Sentry IVC filter in patients with
documented DVT or PE, or at temporary risk of developing
DVT or PE, and with a contraindication to anticoagulation.
MATERIALS AND METHODS
Study Design and Conduct
The prospective, multicenter, nonrandomized, single-arm
SENTRY Clinical Trial was conducted at 23 sites in the
United States (n¼ 20), Belgium (n¼ 2), andChile (n¼ 1). The
protocol was approved by the appropriate Institutional Review
Boards or Ethics Committees, and all study procedures were
performed in accordance with the guidelines of good clinical
practice and applicable regulations. Novate Medical was the
sole sponsor of the study, which was conducted under an
investigational device exemption (IDE G110111), in compli-
ancewith applicable provisions of 21CFRParts 50, 54, and 812
and in accordance with the ethical principles of the Declaration
of Helsinki. The study was registered before the start of patient
enrollment (ClinicalTrials.gov ID NCT01975090).
Patients eligible for inclusion were at least 18 years of age
and were determined by their physicians to be at a temporary
(< 60 days) risk of PE. All patients had documented DVT or
PE or a high risk of developing DVT or PE and had a
contraindication to or failure of anticoagulation. The in-
dications for enrollment were consistent with American
College of Radiology (ACR) and Society of Interventional
Radiology (SIR) practice and quality improvement guidelines
(3,12). The SENTRY trial administrative structure is sum-
marized and the determination of patient eligibility is elabo-
rated in Appendix A (available online on the article’s
Supplemental Material page at www.jvir.org).
Patient Population
A total of 129 patients were enrolled from September 2014 to
February 2016. Baseline patient characteristics and medical
history are detailed in Table 1. The patient indications for filter
placement and the reasons for inability to use anticoagulation
therapy are summarized in Table 2. Of the 129 patients, 87
(67.4%) met the criteria for a therapeutic intervention—
including current DVT and PE (14.0%), PE only (8.5%), and
DVT only (45.0%)—whereas 42 (32.6%) met the criteria for
a prophylactic filter placement. All 129 patients had
Visual Synopsis
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Table 1. Baseline Patient Characteristics, Medical History,
and Risk Factors (n ¼ 129)
Variable Value
Age (y)
Mean ± SD 62.6 ± 13.52
Range 21.0–88.0
Male sex, n (%) 73 (56.6%)
BMI (kg/m2)
Mean ± SD 30.5 ± 8.38
Range 17.3–78.1
WHO BMI category (kg/m2), n (%)
Underweight (<18.5) 2 (1.6)
Normal weight (18.5 to <25.0) 24 (18.6)
Overweight (25.0 to <30.0) 45 (34.9)
Obese class I (30.0 to <35.0) 29 (22.4)
Obese class II (35.0 to <40.0) 18 (14.0)
Obese class III (40.0) 11 (8.5)
Race, n (%)
White (non-Hispanic) 107 (82.9)
Black 11 (8.5)
Hispanic 9 (7.0)
Unknown 2 (1.6)
Medical history/risk factors, n (%)
Hypertension 76 (58.9)
Recent surgery (30 d) 33 (25.6)
Diabetes 28 (21.7)
Malignancy 23 (17.8)
Current smoker 21 (16.3)
Morbid obesity 20 (15.5)
Chronic pulmonary disease 18 (14.0)
Gastrointestinal bleeding 17 (13.2)
Cerebrovascular event 16 (12.4)
Ischemic heart disease 15 (11.6)
Myocardial infarction 13 (10.1)
Congestive heart failure 12 (9.3)
Renal insufficiency/failure 11 (8.5)
Urogenital bleeding 8 (6.2)
Liver insufficiency/failure 6 (4.7)
Hormone replacement therapy 5 (3.9)
Respiratory failure 4 (3.1)
Pacemaker or defibrillator 4 (3.1)
BMI ¼ body mass index; WHO ¼ World Health Organization.
Table 2. Baseline Indications for Filter Placement and
Anticoagulation Status (n ¼ 129)
Variable Value, n (%)
Indications for filter placement
VTE status
Current PE only 11 (8.5)
Current DVT only 58 (45.0)
Current DVT and PE 18 (14.0)
Prophylactic indication* 42 (32.6)
Other thromboembolic risk factors
History of PE 27 (20.9)
History of DVT 30 (23.3)
Trauma with high PE risk 13 (10.1)
Surgery with high PE risk 87 (67.4)
Medical condition with high PE risk 39 (30.2)
Primary factor for filter placement
Surgery 77 (59.7)
Medical condition 28 (21.7)
Trauma 8 (6.2)
Other 16 (12.4)
Reasons for inability to use anticoagulation therapy
Inability to use anticoagulation during
the transient risk period
129 (100.0)
Risk of bleeding and/or injury
from anticoagulation
79 (61.2)
Contraindication 49 (38.0)
Failure 17 (13.2)
Inability to achieve/maintain
adequate anticoagulation
10 (7.8)
Recurrent PE despite adequate therapy 3 (2.3)
Propagation/progression of DVT
during therapeutic anticoagulation
4 (3.1)
Complication of anticoagulation 3 (2.3)
Noncompliance of anticoagulation 1 (0.8)
Other failure of anticoagulation 7 (5.4)
DVT ¼ deep vein thrombosis; PE ¼ pulmonary embolism;
VTE ¼ venous thromboembolism.
*Prophylactic indication: no current PE or DVT but high risk of PE.
Volume 29 ▪ Number 10 ▪ October ▪ 2018 1353permanent or temporary inability to use anticoagulation. Some
patients had more than 1 contraindication.
Study Device and Procedure
The Sentry IVC filter (Fig 1) is made from a single piece of
laser-cut nitinol, which is formed into a cylindrical frame
with an integral filter cone consisting of 6 pairs of arms held
together in the center of the IVC by means of a bio-
absorbable filament composed of poly-p-dioxanone, a
biodegradable synthetic polymer. During bioconversion, the
bioabsorbable filament hydrolyzes, releasing the filtering
arms from the filtering cone. The filtering arms then retractto the IVC wall into a nonfiltering configuration. This
design allows temporary protection against PE followed by
restoration of IVC lumen patency. The Sentry is indicated
for use in IVCs with diameters of 16–28 mm and has a
maximum deployed length of 57.7 mm. Detailed des-
cription of the Sentry filter and the implantation procedure
is provided in Appendix B (available online on the article’s
Supplemental Material page at www.jvir.org).Study Follow-up and Imaging Evaluation
After device implantation, according to an intensive FDA-
approved schedule, patients were evaluated at 1 month
(range 30–44 days), 2 months (60–67 days), 6 months (150–
210 days), and 12 months (335–395 days). Each follow-up
visit included clinical assessment for symptoms of PE and
DVT, monitoring of adverse events, and assessment of
VTE risk factors. Imaging for filter configuration and
Figure 1. Photographs of the Sentry IVC filter in coronal view
and representations of the axial view: (left) filtering configura-
tion; (right) bioconverted configuration. In the filtering configu-
ration, the 6 pairs of filter arms are held together in the center of
the lumen by means of the bioabsorbable filament composed of
poly-p-dioxanone. In the bioconverted configuration, the bio-
absorbable filament will have been degraded via hydrolysis,
allowing the filter arms to release from the cone and retract to-
ward the IVC wall to be endothelialized, leaving an unobstructed
IVC lumen.
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phy of the lower extremities and computerized tomographic
(CT) venography at 1 month and anterior-posterior and
lateral x-ray (or by CT venography if thrombus was observed
at 1 month) at 2 months. Imaging for filter bioconversion
status and complications was performed with the use of CTat
6 months, anterior-posterior and lateral x-ray at 12 months,
and CT venography at 24 months. The study core laboratory
reviewed all CT imaging for filtering status, the presence of
thrombus, and filter-related complications.
Study End Points
Study end points were formulated in accordance with
SIR reporting standards (24) and ACR guidelines (3) andwith reference to recent IDE studies (25–28). The pre-
defined primary end point was clinical success at 6 months,
a composite of technical success (filter deployment as
intended without acute events), freedom from symptomatic
PE through 60 days, and 6-month freedom from filter-
related complications, including tilting, migration, emboli-
zation, fracture, perforation, symptomatic caval thrombosis,
any other symptomatic filter-related complication requiring
invasive intervention, or filter-related death.
Secondary efficacy end points included: the technical
success rate at day 0; filter status at months 1 and 2 (the
percentage of patients with devices in filtering configura-
tion, based on all 6 pairs of arms being held together in the
central portion of the IVC lumen, and the percentage in
nonfiltering configuration with arms separated from the
central portion of the lumen); bioconversion status at
months 6, 12, and 24 (the percentages bioconverted and the
percentages not converted); and new symptomatic PE
through 6, 12, and 24 months. Secondary and safety end
points are further specified and defined in Appendix C
(available online on the article’s Supplemental Material
page at www.jvir.org).Statistical Analysis
For the statistical analysis on the primary end point of
clinical success at 6 months, the observed rate was tested
against the acceptance criterion by means of the 2-sided
95% Wilson confidence interval (CI) for the binomial pro-
portion. If the lower confidence limit for the true proportion
was  80%, the end point was deemed to be successfully
achieved. In accordance with the calculation outlined in the
study protocol, a sample size of 108 patients at 6 months
was determined to be sufficient to test the primary end point
statistical hypothesis. For the secondary end points and
other clinical outcomes data, the number and percentage of
observed patients for each end point were determined, and
where appropriate the 2-sided 95% CI using the Wilson
score interval around the proportion was calculated. Base-
line patient characteristics and medical history were sum-
marized with the use of statistics including frequency counts
and percentages for categoric variables and means and SDs
for continuous variables.RESULTS
A total of 63 investigators performed the implantations of
the Sentry IVC filter in 129 patients at 23 sites. Study patient
disposition through 12 months is detailed in Figure 2.Filter Placement Procedures
A Sentry device was successfully implanted in all 129 pa-
tients. In 1 patient the filter could not be advanced through
the introducer sheath (owing to resistance experienced by
the investigator) in the left femoral vein. In that case, a
second Sentry filter was successfully deployed via the same
left femoral vein, and there were no clinical sequelae
Figure 2. Disposition of the 129 enrolled patients through
12-month follow-up in the SENTRY Clinical Trial.
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Material page at www.jvir.org]). Following deployment in
all 129 patients, the protocol-mandated venography veri-
fied that all implanted filters were in the intended location
and in the filtering configuration. Postdeployment
venography also confirmed that the IVC was patent in all
patients. In 3 cases, the investigator attached the loading
tool to the introducer sheath in the incorrect orientation,
and as a result the deployment occurred with the apex of
the filter directed caudally. There were no adverse events
associated with these 3 deployments (Appendix D
[available online on the article’s Supplemental Material
page at www.jvir.org]).
The access site for filter placement was the right internal
jugular vein in 64 patients (49.6%), the right femoral vein in
54 patients (41.9%), and the left femoral vein in 11 patients
(8.5%). Mean preimplantation IVC diameter (average of
anterior-posterior and lateral measurements according to
cavogram) was 19.3 ± 2.23 mm (range 14.0–26.0 mm), and
mean preimplantation infrarenal IVC length (measured be-
tween the caudal renal vein and the iliac confluence) was
10.8 ± 1.45 cm (range 9.0–15.2 cm). Two protocol (eligi-
bility) deviations occurred when patients were enrolled with
IVC diameters < 16 mm.Filter Efficacy Outcomes
Results for the composite primary filter efficacy end point of
clinical success at 6 months are detailed in Table 3. All 3 of the
component criteria were met by 111 (97.4%) of 114 patients
evaluable for the composite end point (95% CI 92.5%–
99.1%). Because the 92.5% lower limit of the 95% CI
exceeds 80%, the Sentry IVC filter passed the predefined
acceptance criteria for demonstrating efficacy on the
clinical success end point. Technical success of
deployment was achieved in 99.2% (129/130) of
deployment attempts (95% CI 95.8%–99.9%). The rate
of freedom from new symptomatic PE through 60 days
was 100% (n ¼ 129; 95% CI 97.1%–100.0%), regardless
of whether the indication for device placement was
therapeutic or prophylactic. The rate of freedom from
IVC filter–related complications through 6 months was
98.2% (112/114, 95% CI 93.8%–99.5%), based on findings
of symptomatic caval thrombosis in 2 patients—1 with a
therapeutic indication and 1 with a prophylactic
indication—during the first month of follow-up. The 2
cases of caval thrombosis were adjudicated by the the
clinical events committee (CEC) as serious adverse events
having an unknown relationship to the device and pro-
cedure, because it was not possible to determine whether
the thrombus was captured by or generated by the filter.
After successful treatment with thrombectomy and throm-
bolysis in both cases of symptomatic caval thrombosis, the
2-month follow-up confirmed that the filter was in correct
filtering configuration, and there was no recurrence of the
caval thrombosis in either patient (Appendix D [available
online on the article’s Supplemental Material page at
www.jvir.org]). Through 12-month follow-up, no further
cases of symptomatic caval thrombosis were noted.
No new symptomatic PEs were noted (Table 3), and there
were no other imaging or symptomatic filter-related com-
plications at the scheduled follow-up visits through 12
months. There were no deaths adjudicated to be filter
related.Filter Configuration and Bioconversion
Results
The Sentry is designed to provide filtering protection for a
minimum duration of 60 days and then to bioconvert to a
nonfiltering configuration when the bioabsorbable filament
hydrolyzes, releasing the filter arms for retraction to the
IVC wall. Table 4 summarizes the filter status for all
patients with imaging assessment at 1 and 2 months and
the bioconversion status for all patients with imaging
assessment at 6 and 12 months. Figure 3 presents
representative CT imaging for a single patient. At the
1-month follow-up, 100% of the devices (119/119) were
in filtering configuration, and at the 2-month follow-up,
95.3% (101/106) remained in filtering configuration.
Through follow-up of  12 months, there were no device-
related adverse events or new symptomatic PE in the 5
patients whose devices were not in full filtering
Table 3. Filter Efficacy Outcomes
Variable n (%) 95% CI (%)
Primary composite end point of clinical
success at 6 months
111/114 (97.4) 92.5–99.1
Components of the primary composite end point
Technical success per filter deployment attempt* 129/130 (99.2) 95.8–99.9
Freedom from symptomatic PE through 60 days 129/129 (100.0) 97.1–100.0
Freedom from IVC filter–related
complications through 6 months†
112/114‡ (98.2) 93.8–99.5
Through 60 days 61–210 days 211–395 days
Symptomatic PE 0/129 (0) 0/126 (0) 0/117 (0)
1 mo (n ¼ 129) 2 mo (n ¼ 119) 6 mo (n ¼ 114) 12 mo (n ¼ 111)
Filter-related imaging complication
Tilting 0 (0) 0 (0) 0 (0) 0 (0)
Migration 0 (0) 0 (0) 0 (0) 0 (0)
Perforation 0 (0) 0 (0) 0 (0) 0 (0)
Embolization 0 (0) 0 (0) 0 (0) 0 (0)
Fracture 0 (0) 0 (0) 0 (0) 0 (0)
Any imaging complication 0 (0) 0 (0) 0 (0) 0 (0)
0–1 mo (n ¼ 129) 1–2 mo (n ¼ 127) 2–6 mo (n ¼ 126) 6–12 mo (n ¼ 117)
Filter-related symptomatic complication
Filter-related death 0 (0) 0 (0) 0 (0) 0 (0)
Symptomatic caval thrombosis† 2 (1.6) 0 (0) 0 (0) 0 (0)
Other symptomatic complications
requiring invasive intervention
0 (0) 0 (0) 0 (0) 0 (0)
CI ¼ confidence interval; PE ¼ pulmonary embolism.
*One deployment failure occurred when the filter could not be advanced through the introducer sheath in the left femoral vein; a
second Sentry filter was successfully deployed via the same left femoral vein, and there were no clinical sequelae.
†Two cases of symptomatic caval thrombosis developed and were successfully treated during the first month of follow-up.
‡Of the 115 patients who underwent the protocol-mandated 6-month imaging, 1 patient was imaged 2 days before the beginning of the
window for 6-month imaging and was not included in the denominator for this end point.
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from days 61 to 67).
At the 6-month follow-up, 95.7% of the filters (110/115)
were confirmed by the core laboratory to be bioconverted.
Through 12 months there were no new DVT, PE, or IVC
filter–related complications reported in any of the 5 patients
whose devices were not bioconverted at 6 months, and by
12-month follow-up 3 of the 5 devices had bioconverted. On
all CT imaging performed at any time point, there were no
instances of filter perforation of the IVC wall.
Secondary VTE Outcomes
All patients available for follow-up were reported to be
free from new symptomatic PE through 60 days (n ¼ 126),
6 months (n ¼ 117), and 12 months (n ¼ 111). Ultraso-
nography of the lower extremities was performed  7 days
before the index procedure and at 1-month follow-up to
assess for the presence of DVT. After 1 month, there was
no protocol-mandated lower-extremity imaging, and
DVT status was assessed based on symptoms and any site-
performed imaging that was part of follow-up of high-risk
patients. Through 60 days, the rate of new or worseningDVT was 7.8% (10/129). There were 8 cases of new DVT
and 3 cases of worsening DVT confirmed by the CEC in
10 patients. One patient experienced both a new and a
worsening DVT (Appendix E [available online on the
article’s Supplemental Material page at www.jvir.org]).
The protocol-mandated 1-month CT venography
revealed the presence of thrombus in the filters of 18
(15.8%) of 114 patients with core laboratory review. The
thrombus was symptomatic only in the 2 noted cases of
symptomatic caval thrombosis (Appendix E [available
online on the article’s Supplemental Material page at
www.jvir.org]).
In 2 cases in which patients developed new transient VTE
risks after the 60-day protection period, the placement of a
second IVC filter (a Günther Tulip [Cook Medical, Bloo-
mington, Indiana]) was required above the bioconverted
study device. In the first of these 2 cases, the patient was
readmitted for epistaxis 125 days after the index procedure,
and warfarin was stopped and reversed. In this patient, the
new implantation was adjudicated to be due not to the study
device or the index procedure but to the new VTE risk
(contraindication to anticoagulation due to epistaxis). The
Table 4. Filter Configuration and Bioconversion Status
through 12 Months (n ¼ 129)
Variable Value
Filtering status through 60 days
After implantation
Patients with imaging assessments 126
Filters in filtering configuration* 129 (100.0)
95% CI (%) 97.1–100.0
1-month imaging
Patients with imaging assessments 119
Filters in filtering configuration 119 (100.0)
95% CI (%) 96.9–100.0
2-month imaging
Patients with imaging assessments 106
Filters in filtering configuration 101 (95.3)
95% CI (%) 89.4–98.0
6 mo 12 mo
Filter bioconversion status
Patients with imaging assessments 115 110
Patients bioconverted† 110 (95.7) 106 (96.4)
95% CI (%) 90.2–98.1 91.0–98.6
Patients not bioconverted 5 (4.3) 4 (3.6)
95% CI (%) 1.9–9.8 1.4–9.0
CI ¼ confidence interval.
*Filtering configuration: all 6 filter arms held in the central
portion of the IVC lumen.
†Bioconverted:  1 filter arm separated from the central
portion of the IVC lumen; not bioconverted: all 6 filter arms
remaining held in the central portion of the IVC lumen.
Volume 29 ▪ Number 10 ▪ October ▪ 2018 1357second patient had been originally enrolled after an open
cystoprostatectomy for small-cell bladder cancer and recent
gastrointestinal bleeding. The new filter implantation was
performed when a hemorrhagic brain metastasis was iden-
tified 137 days after the index procedure. This event also
was considered to be due to a new VTE risk involving
contraindication to anticoagulation and not to the study
device or index procedure.
Safety
In the entire safety analysis population of 129 patients,  1
adverse events were experienced by a total of 85 (65.9%)
through 210 days after implantation (the end of the window
for 6-month follow-up) and by 58 (49.6%) from 211 to 395
days (the end of the window for 12-month follow-up). One
or more serious adverse events were experienced by 47
patients (36.4%) through 210 days after implantation and by
16 patients (13.7%) from 211 to 395 days (Table 5). None
of the serious adverse events were confirmed by the CEC as
being related to the filter. One case of a new symptomatic
DVT—swelling in the right leg, with ultrasonography
showing clotting extending from the filter down into the
right iliac vein and to the right calf—with onset 8 days
after the index filter implantation was adjudicated to be
procedure related, due to access site thrombosis. Aftertreatment with anticoagulation, the Sentry device was in
filtering configuration at 1- and 2-months follow-ups and
was confirmed to be bioconverted at 6 months, with the
patient experiencing no further clinical events. None of the
12 deaths through 12 months (due to cancer [n ¼ 3], car-
diopulmonary arrest [n ¼ 2], respiratory failure [n ¼ 3],
multiorgan failure, hypertensive cardiovascular disease,
liver failure, and myasthenia gravis) were related to the
Sentry filter or to the index procedure, as reported by the
sites and confirmed by CEC adjudication.
At study baseline, all 129 enrolled patients were reported
by the sites to have permanent, temporary, or predicted
contraindications to anticoagulation. The overall anti-
coagulation status of the patients changed as their conditions
progressed during the course of the study, and when there
was no longer a contraindication, the decision whether to
administer anticoagulation was left to each individual
physician (Table 6).DISCUSSION
In the present imaging-intense IDE trial of the Sentry
bioconvertible IVC filter, the composite primary end point
of clinical success at 6 months was achieved in 97.4% of
evaluable patients (111/114), with the 92.5% lower limit
of the 95% CI surpassing the 80% SIR trial performance
objective. The 3 failures on the composite end point
included the need for a second (successful) implantation
attempt in 1 patient and the occurrence within the first
month of symptomatic caval thrombosis in 1 patient with a
therapeutic indication and in 1 with a prophylactic indi-
cation (both cases adjudicated to have an unknown rela-
tionship to the device and procedure, successfully treated
with thrombectomy and thrombolysis, and subsequently
showing no recurrence). The 99.2% rate of deployment
technical success exceeded the established 97% SIR
threshold value (12).
There were no cases of new symptomatic PE through 60
days before filter bioconversion and this extended through
the 12-month follow-up. This outcome compares favorably
with 6-month PE rates ranging from 1% to 8% in recent
trials of retrievable IVC filters (25–29). Through 60 days,
the incidence of new or worsening DVTwas 7.8% (10/129),
similar to recent findings for retrievable filters (25–29) and
considerably better than the rates reported for permanent
filters in the PREPIC study (30); none of the DVTs were
confirmed to be device related, and 1 that occurred at 8 days
was considered to be procedure related. Of the 18 patients
with confirmed thrombus in their filters at protocol-
mandated 1-month CT venography, only 2 (the cases of
caval thrombosis) were symptomatic, and there were no
further VTE-related events, symptomatic PE, or adverse
events either before or after the bioconversion of their filters
for those patients.
Through the scheduled follow-ups at 1, 2, 6, and 12
months, there was no filter tilting, migration, perforation,
embolization, fracture, or filter-related death noted. Allowing
Figure 3. Representative CT imaging for a single patient. (a) Coronal image acquired as part of helical dataset 1 month after filter
placement, showing the Sentry device in filtering configuration. (b) Coronal image at 6-month follow-up showing the device in
bioconverted configuration. (c–e) Axial views of the bioconverted device at 6-month follow-up, with the images keyed to the coronal
view in (b).
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thrombosis, the rate of freedom from IVC filter-related
complications through 6 months was 98.2% (112/114),
and there were no further cases of symptomatic caval
thrombosis through 12 months. In comparison, device-
related complications have been a matter of increasing
concern with indwelling retrievable IVC filters and have
been found to occur at a greater rate than with permanent
filters (17,19,22). The need to develop devices that will
effectively trap emboli and preserve retrievability has
resulted in design compromises that appear to be associated
with less secure implantation than the permanent filters (21),
leading to complications such as tilting, migration, embo-
lization, perforation, and fracture (21,31). Although the
majority of retrievable IVC filters are placed to provide
short-term protection against PE after index events
including surgery, trauma, and hospitalization, rates ofretrieval vary widely between centers and are often as low as
20%–35% (20,21), despite the 2010 FDA safety commu-
nication about the potential for long-term complications,
which was updated in 2014 (4,7,16,27,32). The factors that
have been noted as responsible for retrievable filters being
left in place for long periods or permanently include tech-
nical failure during retrieval attempts, endothelialization,
and lack of patient compliance (4,11,14,22). Whereas the
rate of filter retrieval may not have increased appreciably
since the FDA advisory, a recent study has documented a
29.0% decrease in IVC filter placement from 2010 to 2014
while the rate of hospitalizations related to VTE remained
steady (33).
Regarding the design concept and rationale for the
Sentry IVC filter to provide protection until bioconversion
after 60 days after implantation, contemporary data sup-
port the premise that the period of highest risk for PE in
Table 6. Patient Anticoagulation Status through 12 Months, n (%)
Status Days –7 to –1 Device
Deployment,
Day 0
Days 1–7 Day 7 to
Month 1
(Days 8–44)
Months 1–2
(Days 45–67)
Months 2–6
(Days 68–210)
Months 6–12
(Days 211–395)
n 129 129 129 128 127 126 117
No anticoagulation*
use for all
or part of the interval
95 (73.6) 72 (55.8) 80 (62.0) 65 (50.8) 42 (33.1) 71 (56.3) 68 (58.1)
Continuous
anticoagulation*
for the interval
34 (26.4) 57 (44.2) 49 (38.0) 63 (49.2) 85 (66.9) 55 (43.7) 49 (41.9)
*Anticoagulants included heparin, factor Xa inhibitors, direct thrombin inhibitor, factor II inhibitor, and Coumadin derivatives. A pa-
tient could use >1 anticoagulant medication within the same time interval.
Table 5. Serious Adverse Events (SAEs) by System Organ Class (n ¼ 129), n (%)
Category Patients with ≥ 1 SAE,
days 0–210*
Patients with ≥ 1 SAE,
days 211–395†
All patients, all SAEs 47 (36.4) 16 (13.7)
Blood and lymphatic system disorders 5 (3.9) 0 (0)
Cardiac disorders 10 (7.8) 3 (2.6)
Congenital, familial, and genetic disorders 0 (0) 1 (0.9)
Gastrointestinal disorders 5 (3.9) 2 (1.7)
General disorders and administration site conditions 3 (2.3) 0 (0)
Infections and infestations 18 (14.0) 2 (1.7)
Injury, poisoning, and procedural complications 4 (3.1) 2 (1.7)
Metabolism and nutrition disorders 4 (3.1) 0 (0)
Musculoskeletal and connective tissue disorders 2 (1.6) 3 (2.6)
Neoplasms benign, malignant, and unspecified (including cysts and polyps) 5 (3.9) 3 (2.6)
Nervous system disorders 5 (3.9) 0 (0)
Psychiatric disorders 0 (0) 1 (0.9)
Renal and urinary disorders 5 (3.9) 2 (1.7)
Respiratory, thoracic, and mediastinal disorders 9 (7.0) 1 (0.9)
Skin and subcutaneous tissue disorders 0 (0) 1 (0.9)
Surgical and medical procedures 1 (0.8) 1 (0.9)
Vascular disorders 3 (2.3) 0 (0)
*The window for 6-month follow-up ended at 210 days after implantation.
†The window for 12-month follow-up ended at 395 days after implantation.
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lants occurs early. In one study in a group of trauma pa-
tients, the average time from injury to PE was determined
to be 7.9 days (34), and other studies have found that the
majority of trauma-related PE occur < 30 days after
the index event (7–9). In studies of postoperative PE, the
mean time from surgery to PE was 3–20 days (10,35,36).
The majority of inpatient PE after orthopedic surgery
occur by 35 days after the procedure (37,38). According to
a decision analysis with mathematical modeling developed
by the FDA, if the transient risk for PE has passed, the
risk/benefit profile begins to favor removal of a retrievable
filter from 29 to 54 days after the index implantation (14).
The protection period of up to 60 days offered by the
Sentry filter extends comfortably beyond the term of risk
demonstrated by these data. Indeed, in this trial no patientsrequired an extension of the protection period, and no
patients suffered a new symptomatic PE at any time point
through the current 12-month follow-up.
In the present study, 100% of the filters were in stable
filtering configuration at the 1-month protocol-mandated
imaging, and 95.3% remained so at 2 months. Then
95.7% had successfully bioconverted by 6 months, and at
the 12-month follow-up 96.4% (106/110) were confirmed to
be bioconverted. The rate of bioconversion for the Sentry
filter contrasts favorably with the retrieval rates (as noted
above) for retrievable filters. The efficacy and safety out-
comes for the Sentry through 12 months contrast favorably
with the noted occurrence of long-term complications
associated with indwelling retrievable filters.
As with recent interim reports on trials of retrievable IVC
filters, limitations of the present study include the
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for bias in a manufacturer-funded regulatory device trial.
Although the rate of freedom from symptomatic PE was
100% through 60 days before filter bioconversion and then
extending through the 12-month follow-up for the full pa-
tient cohort, it is possible that instances of asymptomatic PE
may have gone undetected (which is consistent with other
IVC filter studies) because imaging was performed only in
patients with suggestive clinical symptoms. Whereas the
currently reported 1-year outcomes support the viability of
this novel approach to providing temporary protection
against PE, longer-term follow-up in a broader patient
population will be important to confirm the durability of
efficacy and safety outcomes and to ensure that the benefit
of avoiding the need for device retrieval does not come with
as yet unforeseen costs. The 24-month follow-up, which
will be separately reported, includes CT venography, and
any further filter-related complications will be described,
including loss of IVC patency after capture of thrombus or
any thrombogenicity associated with retracted filter arms.
IVC diameter at the level of filter placement was not eval-
uated in 60-day imaging but will be reported for the 24-
month follow-up.
In this 1-year interim analysis of the SENTRY clinical
trial data, for patients requiring temporary protection against
PE and unable to use anticoagulation, the Sentry IVC filter
showed high rates of technical and clinical success and
minimal complications, within the efficacy and safety
thresholds suggested by SIR and comparing favorably with
outcomes reported for retrievable IVC filters. The results of
this trial suggest that this bioconvertible device may provide
an alternative to existing retrievable IVC filters that often
remain indwelling long after the period of transient PE risk
has passed and that are associated with relatively high
complication rates.ACKNOWLEDGMENTS
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The CME questions in this issue are derived from the article “One-Year Analysis of the Prospective Multicenter SENTRY
Clinical Trial: Safety and Effectiveness of the Novate Sentry Bioconvertible Inferior Vena Cava Filter” by Dake et al.
In this study, the authors prospectively assess the bioconvertible Sentry inferior vena cava (IVC) filter in patients requiring
temporary protection against pulmonary embolism (PE).
1. Based on prior published data, approximately what
percentage of filters remain unretrieved, thus risking an
increase in filter-specific complications?
a. 10–20%.
b. 25–50%.
c. 60–80%.
d. > 90%.
2. Based on the results of this study, what percentage of
patients were free from IVC filter related complications
at 6 months?
a. 20%.
b. 50%.
c. 70%.
d. > 95%.
3. Based on the results published in this study, what was
the incidence of filter migration and/or perforation of
the caval wall by 1 or more filter struts at 1 year
following implantation?
a. 0%.
b. 1%.
c. 2%.
d. > 5%.
4. The IVC filter use in this study is designed to provide
filtering protection for a minimum duration of 60 days
and then bioconvert to a nonfiltering configuration.
What was the reported success rate of filter biocon-
version at 60 days in this study?
a. 2.1%.
b. 3.5%.
c. 4.3%.
d. 5.2%.
APPENDIX A. STUDY DESIGN
Study Administration
The prospective, multicenter, nonrandomized, single-arm
SENTRY Clinical Trial was conducted at 23 sites in the
United States (n ¼ 20), Belgium (n ¼ 2), and Chile (n ¼ 1).
The protocol was approved by the appropriate Institutional
Review Boards or Ethics Committees, and all study pro-
cedures were performed in accordance with the guidelines
of good clinical practice and applicable regulations. Novate
Medical was the sole sponsor of the study, which was
conducted under an investigational device exemption (IDE
G110111), in compliance with applicable provisions of 21
CFR Parts 50, 54, and 812 and in accordance with the
ethical principles of the Declaration of Helsinki. Data were
collected on case report forms (with supervision by Vitru-
vian Clinical Research, San Ramon, California) and
reviewed and adjudicated by an independent data moni-
toring committee and a clinical events committee (CEC).
Global Institute for Research (Richmond, Virginia) served as
the imaging core laboratory, providing independent measure-
ment and analysis in accordance with the predefined study
protocols. QST Consultations (Allendale, Michigan) devel-
oped the statistical hypothesis for the study, and Advanced
Research Associates (Santa Clara, California) defined the
statistical analysis plan and methods and provided statistical
analysis support. The study was registered before the start of
patient enrollment (ClinicalTrials.gov ID NCT01975090).
Patient Eligibility Determination
Patients eligible for inclusion were  18 years of age and
were determined by their physicians to be at a temporary
(< 60 days) risk of pulmonary embolism (PE). All patients
had documented deep vein thrombosis (DVT) or PE, or a
high risk of developing DVT or PE, and had a contraindi-
cation to or failure of anticoagulation. The trial allowed
enrollment of up to 40% of patients with a prophylactic
indication (no current PE or DVT but high risk of PE). The
indications for enrollment were consistent with American
College of Radiology and Society of Interventional Radi-
ology practice and quality improvement guidelines. Patients
were required to have an average inferior vena cava (IVC)
diameter of 16–28 mm and an infrarenal IVC length 9 cm.
Patients were excluded if they were pregnant or planning to
become pregnant within 12 months, had impaired renal
function (serum creatinine  2.0 mg/dL), had life expec-
tancy < 12 months, had a malignancy extending the PE
period of risk > 60 days, had a known hypercoagulable
state, or had an inherited or acquired hemostatic disorder.
Venographic and/or procedural exclusion criteria included
presence of a caval stent or IVC filter or history of IVC filter
(< 1 month after retrieval), inability to gain femoral or
internal jugular vein access or infection at the only available
access site, duplicated or left-sided IVC, renal vein throm-
bosis or IVC thrombosis extending to the renal veins,
occlusive or free-floating IVC thrombus, or known allergy
or hypersensitivity to study device materials or to contrast
media (not amenable to premedication). Baseline assess-
ment on consented patients was performed  7 days before
the index procedure, and patient enrollment occurred with
insertion of the Sentry IVC filter introducer sheath.
APPENDIX B. THE SENTRY IVC FILTER
AND IMPLANTATION TECHNIQUE
Device Design and Mechanism
The Sentry inferior vena cava (IVC) filter is made from a
single piece of laser-cut nitinol, which is formed into a cy-
lindrical frame with an integral filter cone consisting of 6
pairs of arms held together in the center of the IVC by
means of a bioabsorbable filament composed of poly-p-
dioxanone, a biodegradable synthetic polymer. The nitinol
frame is designed to concentrically and longitudinally
distribute radial force to decrease device tilting, migration,
perforation, and fracture. Six fixation barbs (4 in the cranial
direction and 2 in the caudal direction) are located on the
nitinol frame to minimize device migration. On deployment,
the cylindrical frame expands to appose the IVC wall,
inciting incorporation of portions of the filter into the caval
wall by means of neointimal healing. The Sentry filter was
designed to support clot-trapping efficacy similar to that of
the currently marketed IVC filters, as confirmed by FDA-
mandated in vivo and in vitro bench testing. The device is
nonmagnetic. It is sterilized by ethylene oxide.
During bioconversion, the bioabsorbable filament hy-
drolyzes, releasing the filtering arms from the filtering cone.
The filtering arms then retract to the IVC wall into a non-
filtering configuration, where they are endothelialized along
with the device frame. The mechanism of the filter-arm
retraction is a function of the shape memory properties of
the nitinol. The entire filter is cut from a single piece of
nitinol and expanded to its finished diameter; during this
process the filter arms are oriented in the nonfiltering posi-
tion adjacent to the frame elements. When the bioabsorbable
filament hydrolyzes during bioconversion and releases the
arms, then due to the nitinol properties the arms return to
their set position. This design allows temporary protection
against pulmonary embolism followed by restoration of IVC
lumen patency. The Sentry is indicated for use in IVC with
diameters from 16 to 28 mm and has a maximum deployed
length of 57.7 mm.
Device Implantation
The study investigators were instructed to obtain a cavo-
gram with the use of an IVC sizing catheter to determine the
diameter of the IVC and the infrarenal length at the im-
plantation site (the cranial end of the filter to be landed  2
cm below the caudal renal vein). The IVC diameter was
measured in both the anterior-posterior and lateral planes,
with the mean diameter confirmed to be within the specified
range of 16–28 mm. The infrarenal IVC length was
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measured between the caudal renal vein and the iliac
confluence and was required to be > 9 cm.
The Sentry filter comes preloaded in a bidirectional car-
tridge, which can be inserted through the custom 7-F
introducer sheath for deployment by means of a femoral
or jugular approach. Upon attainment of vascular access, a
guidewire is advanced into the IVC over which the intro-
ducer sheath and dilator are advanced to the intended
deployment site, with the cranial marker band used for
positioning  2 cm below the most caudal renal vein. After
removal of the dilator and guidewire and the confirmatory
cavogram measurement, the loading tool (containing the
preloaded filter) is oriented according to the access route
with reference to the femoral and jugular labels and inserted
into the hub of the introducer sheath. The device pusher is
then used to advance the filter through the loading tool and
into the introducer sheath to the intended deployment
location (when the deployment indicator on the pusher ap-
proaches the loading tool, the loaded filter is approaching
the tip of the introducer sheath). Deployment is performed
by slowly retracting the outer sheath over the pusher (which
is held stationary).
Following deployment, biplanar venograms were
required in the study to verify that the device was in the
intended location and in the filtering configuration. The
device instructions for use specify that it should not be
placed in a suprarenal position. When the filter implan-
tation was transjugular, a catheter was placed cranial to
the filter, and a retrograde injection of contrast was used
to show the section of the IVC containing the filter. The
study sites were instructed to not cross the filter in per-
forming the postdeployment venography.
APPENDIX C. STUDY END POINTS AND
DEFINITIONS
Study end points were formulated in accordance with the
Society of Interventional Radiology reporting standards
and the American College of Radiology guidelines and
with reference to recent investigational device exemption
studies. The predefined primary end point was clinical
success at 6 months, a composite of technical success
(filter deployment as intended without acute events),
freedom from symptomatic pulmonary embolism (PE)
through 60 days, and 6-month freedom from filter-related
complications, including tilting, migration, embolization,
fracture, perforation, symptomatic caval thrombosis, any
other symptomatic filter-related complication requiring
invasive intervention, or filter-related death.
Symptomatic PE was defined as sudden-onset dyspnea,
hypotension, pleuritic pain, cough, or hemoptysis; confirmed
by means of pulmonary angiography, computerized tomogra-
phy (CT), magnetic resonance imaging, pathologic examina-
tion of thrombus, or ventilation/perfusion lung scan interpreted
as high probability; and categorized as new or recurrent and
fatal or nonfatal. Filter tilt was defined as > 15 tilt off the true
cylindrical axis of the local cava. Filter migration was defined
as a change in filter position of>2 cm (either cranial or caudal)
compared with the deployed position, as documented by plain
film imaging, CT, or venography. Filter embolization was
defined as movement of the filter or its components to a distant
anatomic site completely out of the target zone (heart/lungs), as
documented by imaging or autopsy. Filter fracture was defined
as any loss of structural integrity, as documented by imaging or
autopsy. Filter perforation was defined as penetration of a strut
> 3 mm outside the inferior vena cava (IVC) wall, as
demonstrated by CT, ultrasonography, venography, or autopsy.
Symptomatic caval thrombosis was defined as including the
presence of bilateral lower-extremity swelling or of pain
attributed to impeded venous return, with imaging observation
(or visual confirmation on surgery or autopsy) of thrombus or
filling defect associated with the implanted filter.
Secondary efficacy end points included: the technical suc-
cess rate at day 0; filter status at months 1 and 2 (the per-
centage of patients with devices in filtering configuration,
based on all 6 pairs of arms being held together in the central
portion of the IVC lumen, and the percentage in nonfiltering
configuration with arms separated from the central portion of
the lumen); bioconversion status at months 6, 12, and 24 (the
percentage bioconverted and the percentage not converted);
and new symptomatic PE through 6, 12, and 24 months.
Secondary safety end points included: procedure-related
serious adverse events; freedom from filter-related compli-
cations on day 0 and at months 1, 2, 6, 12, and 24; invasive
filter interventions, such as thrombolysis, thrombectomy,
surgical removal of the filter, placement of a second filter,
and vascular repair of the IVC; and placement of an addi-
tional IVC filter (categorized as filter-related or for exten-
sion of protection from PE beyond 60 days). Other clinical
outcomes included deep vein thrombosis of the lower ex-
tremities, the assessment of VTE risk factors, and anti-
coagulation status on day 0 and at months 1, 2, 6, 12,
and 24.
An adverse event was considered to be a serious adverse
event if it resulted in death, was life-threatening, required or
prolonged hospitalization, resulted in persistent or signifi-
cant disability/incapacity, or was an important medical event
that jeopardized the subject and required medical or surgical
intervention.
A sensitivity analysis of the primary end point of clinical
success at 6 months was performed on the full analysis set
with all missing data considered to be failures. This
approach presented a worst-case scenario.
APPENDIX D. COMPOSITE PRIMARY
FILTER EFFICACY END POINT
OUTCOMES
Primary Efficacy End Point Components
The predefined primary end point was clinical success at 6
months, a composite of technical success (filter deployment as
intended without acute events), freedom from symptomatic
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pulmonary embolism (PE) through 60 days, and 6-month
freedom from filter-related complications, including tilting,
migration, embolization, fracture, perforation, symptomatic
caval thrombosis, any other symptomatic filter-related compli-
cation requiring invasive intervention, or filter-related death.
All 3 of the component criteria were met by 111 (97.4%)
of 114 patients evaluable for the composite end point (95%
CI 92.5%–99.1%). Because the 92.5% lower limit of the
95% CI exceeds 80%, the Sentry IVC filter passed the
predefined acceptance criteria for demonstrating efficacy on
the clinical success end point. Technical success of
deployment was achieved in 99.2% (129/130) of deploy-
ment attempts (95% CI 95.8%–99.9%). The rate of freedom
from new symptomatic PE through 60 days was 100% (n ¼
129; 95% CI 97.1%–100.0%), regardless of whether the
indication for device placement was therapeutic or prophy-
lactic. The rate of freedom from inferior vena cava (IVC)
filterrelated complications through 6 months was 98.2%
(112/114, 95% CI 93.8%–99.5%).
Technical Success of Deployment—One
Failure
In one patient the filter could not be advanced through the
introducer sheath (owing to resistance experienced by the
investigator) in the left femoral vein, which the investigator
had determined to be the most appropriate access route. When
the investigator noted difficulty in advancing the device, the
entire apparatus was withdrawn. Before that system was dis-
carded, the filter was deployed from the kinked introducer
sheath, and it was found to be intact with no apparent damage.
After the withdrawal of the first system, a new system (new
introducer sheath, new device) was successfully deployed
through the same left femoral approach as originally intended.
There were no clinical sequelae.
Filter-Related Complications through 6
Months—Two Cases of Symptomatic
Caval Thrombosis
One of the 2 cases of symptomatic caval thrombosis
occurred, following a protocol deviation, in a prophylactic-
indication patient who had 2 separate underlying congenital
prothrombotic conditions and a history of recurrent PE
despite adequate anticoagulation and who was scheduled for
major spinal surgery, with anticoagulation contraindicated.
After the patient resumed anticoagulation, he developed the
symptomatic caval thrombosis (at 8 days after the index
filter implantation), which was successfully treated with the
use of thrombectomy (Angiojet Thrombectomy System;
Boston Scientific), ultrasound-enhanced thrombolysis, and
percutaneous transluminal angioplasty of the iliac veins,
common femoral vein, and IVC.
The other case of symptomatic caval thrombosis occurred
in a therapeutic-indication patient who had developed
bilateral deep vein thrombosis while recovering from sub-
dural hematoma and a subsequent burr-hole procedure, and
who was not a candidate for anticoagulation. The patient
developed a symptomatic caval thrombosis 32 days after the
filter implantation, which was successfully treated with the
use of thrombolysis (Ekosonic Endovascular System;
EKOS) and mechanical thrombectomy.
The 2 cases of caval thrombosis were both adjudicated by
the study clinical events committee as serious adverse
events having an unknown relationship to the device and
procedure, because it was not possible to determine whether
the thrombus was captured by or generated by the filter. In
both cases of symptomatic caval thrombosis, the 2-month
follow-up confirmed that the filter was in correct filtering
configuration, and there was no recurrence of the caval
thrombosis in either patient.
Three Cases of Incorrect Device
Orientation Not Classified as Deployment
Failures
Three different investigators at 3 different institutions deviated
from the Sentry instructions for use, the study protocol, and
the site training when they attached the loading tool to the
introducer sheath in the incorrect orientation—resulting in
the 3 devices being deployed upside down, with the apex of
the filter directed caudally. No second filter was deployed in
any of these cases, and there were no adverse events associ-
ated with any of the deviations. The incorrect deployments
were reviewed by Novate and attributed to user error.
Per protocol, these 3 cases were not classified as deployment
failures. Had they been adjudicated as deployment failures, the
rate of deployment technical success would have been 96.9%
(126/130). After completion of the trial, the printed arrows and
text on the loading tool of the Sentry IVC filter were modified
to more clearly identify the correct orientation for femoral and
jugular approaches. Additional warnings have also been
included in the device instructions for use.
APPENDIX E. SECONDARY VTE
OUTCOMES
Cases of New or Worsening Deep Vein
Thrombosis
After 1 month, there was no protocol-mandated lower-ex-
tremity imaging, and deep vein thrombosis (DVT) status
was assessed based on symptoms and any site-performed
imaging that was part of the follow-up of high-risk pa-
tients. Through 60 days, the rate of new or worsening DVT
was 7.8% (10/129). There were 8 cases of new DVT and 3
cases of worsening DVT confirmed by the study clinical
events committee (CEC) in 10 patients. One patient expe-
rienced both a new and a worsening DVT.
The DVT noted within the first 2 months of follow-up were
symptomatic in 5 cases. None of the DVTs noted in the first 2
months were confirmed as being device related. One case of a
new symptomatic DVT—swelling in the right leg, with ul-
trasound showing clotting extending from the filter down into
the right iliac vein and to the right calf—with onset 8 days
after the index filter implantation was adjudicated to be
1361.e3 ▪ One-Year Report: Sentry Bioconvertible IVC Filter Dake et al ▪ JVIR
procedure related due to access site thrombosis. After treat-
ment with anticoagulation, the Sentry device was in filtering
configuration at 1- and 2-month follow-ups and was
confirmed to be bioconverted at 6 months, with the patient
experiencing no further clinical events.
One new symptomatic DVTwas reported at 158 days and
was adjudicated as not related to the procedure and as
having an unknown relationship to the study device. One
additional new symptomatic DVT was reported at 224 days
and was adjudicated as being not related to the procedure or
the study device. Through 12 months, there were 2 site-
reported cases of DVT that the CEC determined to be
continuing (1 reported at 7 days, 1 at 287 days).
Findings of Thrombus in Filters
The protocol-mandated 1-month computerized tomographic
(CT) venography revealed the presence of thrombus in the
filters of 18 (15.8%) of 114 patients with core laboratory
review. The thrombus was symptomatic only in the 2 noted
cases of symptomatic caval thrombosis. In CT venography
follow-up that was available at 2 months for 10 of these 18
patients, the thrombus was completely resolved in 3, the
thrombus size had been reduced in 5, the thrombus was
slightly larger in 1 (< 4 mm increase in length while the clot
width decreased), and in 1 the imaging quality did not allow
accurate determination of size although the presence of
thrombus was confirmed. No patient with thrombus in the
filter at 1 month had experienced a pulmonary embolism
(PE) at 2 months, and PE did not occur after bioconversion
of any of the filters that contained thrombus at 1 month. In
13 of these patients who completed follow-up to 12 months,
the filters were reported by the investigators to be bio-
converted in 12. Follow-up through 24 months will be re-
ported for all of these patients.
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